6 结语
Avastin治疗AMD已取得良好效果,不仅较之相似疗效的Lucentis价格更低廉,且与PDT联合治疗有望为患者带来更大福音。但作为标示外应用,也需提醒所有临床医生在治疗前不仅自身应明确该治疗的利弊,更应让患者也有一定了解。由于该疗法实施时间尚短,缺乏长期多中心随机对照研究,故在适应证选择以及远期疗效等方面尚需要深入研究。此外,目前相关的研究绝大多数是国外的工作,尚缺乏以我国患者为对象的高等级的循证医学资料。目前此项工作已启动,预计2年后可以得到Avastin治疗我国AMD患者的初步结果。
【参考文献】
[1] Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis[J]. Ophthalmology,2008,115(1):116-126.
[2] Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration[J]. Curr Opin Ophthalmol,2009,20(3):158-165.
[3] Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration[J]. Expert Opin Investig Drugs,2009,18(5):637-646.
[4] 庄岩,陈有信. 抗血管内皮生长因子单克隆抗体Bevacizumab基础和临床研究现状[J]. 中华眼底病杂志,2008,24 (3):227-231.
[5] 李夏,王雨生. Bevacizumab治疗脉络膜新生血管疾病的现状[J]. 中国实用眼科杂志,2006,24(11):1112-1115.
[6] 于同利,毕宏生. Avastin在眼科应用的研究进展[J]. 国际眼科杂志,2008,8(4):810-812.
[7] Prager F, Michels S, Simader C, et al. Changes in retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (avastin) therapy[J]. Retina,2008,28(5):682-688.
[8] Valmaggia C, Niederberger H, Lang C, et al. The treatment of choroidal neovascularisations with intravitreal injections of bevacizumab(avastin(r))[J]. KlinaMonatsbl Augenheilkd,2008,225(5):380-384.
[9] Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results[J]. Eye,2008,22(1):82-86.
[10] De Clercq C, Snyers B, Guagnini AP, et al. Treatment of age-related macular degeneration with intravitreous injections of bevacizumab(Avastin):short-term results[J]. Bull Soc Belge Ophtalmol,2007,(306):15-21.
[11] Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study[J]. Am J Ophthalmol,2008,145(2):249-256.
[12] Azad RV, Khan MA, Chanana B, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population[J]. Jpn J Ophthalmol,2008,52(1):52-56.
[13] Algvere PV, Steén B, Seregard S, et al. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations[J]. Acta Ophthalmol,2007,86(5):482-489.
[14] Schaal KB, Engler C, Schütt F, et al. Dithmar S.Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD[J]. Ophthalmologe,2008,105(6):538-543.
[15] Jonas JB, Libondi T, Ihloff AK, et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type[J]. Acta Ophthalmol Scand,2007,85(5):563-565.
[16] Levy J, Shneck M, Rosen S, et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration[J]. Int Ophthalmol,2008 Jun 11
[17] Melamud A, Stinnett SA, Fekrat S. Treatment of Neovascular Age-related Macular Degeneration with Intravitreal Bevacizumab: Efficacy of Three Consecutive Monthly Injections[J]. Am J Ophthalmol,2008,146(1):91-95.
[18] Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage[J]. Am J Ophthalmol,2007,144(6):886-892.
[19] 王雨生,李夏(述评). 脉络膜新生血管性疾病联合治疗的效果及其存在的问题[J]. 眼科,2007,16(4):226-228.
[20] Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration[J]. Ophthalmology,2007,114(6):1179-1185.
[21] Smith BT, Dhalla MS, Shah GK, et al. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration[J]. Retina,2008,28(5):675-681.
[22] Dhalla MS, Shah GK, Blinder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration[J]. Retina,2006,26(9):988-993.
[23] Soheilian M, Riazi-Esfahani M, Ahadi H. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration[J]. Eur J Ophthalmol,2008,18(2):297-300.
[24] Maier M, Haas K, Feucht N, et al. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for occult and classic CNV in AMD[J]. Klin Monatsbl Augenheilkd,2008,225(7):653-659.
[25] Ladewig MS, Karl SE, Hamelmann V, et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration[J]. Graefes Arch Clin Exp Ophthalmol,2008,246(1):17-25.
[26] Shah AR, Del Priore LV. Duration of Action of Intravitreal Ranibizumab and Bevacizumab in Exudative AMD Eyes Based on Macular Volume Measurements[J]. Br J Ophthalmol,2009 May 7. [Epud ahead of print]
[27] Valmaggia C, Haueter I, Kloos P, et al. The treatment of choroidal neovascularizations in age-related macular degeneration using either Avastin or Lucentis[J]. Klin Monatsbl Augenheilkd,2009,226(4):294-298.
[28] Karagiannis DA, Mitropoulos P, Ladas ID. Large Subretinal Haemorrhage following Change from Intravitreal Bevacizumab to Ranibizumab[J]. Ophthalmologica,2009,223(4):279-282.
[29] Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab, safety survey: using the internet to assess drug safety world-wide[J]. Br J Ophthalmol,2006,90(11):1344-1349.
[30] Garg S, Brod R, Kim D ,et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration[J]. Clin Experiment Ophthalmol,2008,36(3):252-256.
[31] Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab[J]. Can J Ophthalmol,2007,42(6):807-811.
[32] Hasler S, Schmid MK, Becht CN, et al. Acute anterior non-granulomatous uveitis after intravitreal injection of bevacizumab[J]. Klin Monatsbl Augenheilkd,2008,225(5):446-447.
[33] Krebs I, Ansari-Shahrezaei S, Goll A, et al. Activity of neovascular lesions treated with bevacizumab:comparison between optical coherence tomography and fluorescein angiography[J]. Graefes Arch Clin Exp Ophthalmol,2008,246(6):811-815.
[34] Vaclavik V, Vujosevic S, Dandekar SS, et al. Autofluorescence imaging in age-related macular degeneration complicated by choroidal neovascularization:a prospective study[J]. Ophthalmology,2008,115(2):342-346.
[35] Heimes B, Lommatzsch A, Zeimer M, et al. Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD[J]. Graefes Arch Clin Exp Ophthalmol,2008, 246(9):1229-1234. 上一页 [1] [2] [3] |